Browsing by Author Taskinen, M.

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 9 of 9
Issue DateTitleAuthor(s)Citation
2010Ability of traditional lipid ratios and apolipoprotein ratios to predict cardiovascular risk in people with type 2 diabetesBarter, Philip; Keech, Anthony (Tony); Mann, Kirsty; Simes, Robert John; Best, J; Ehnholm, Christian; Hamwood, S; Sullivan, David Richmond; Taskinen, M.; Central Clinical School: Heart Research Institute; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials CentreAbility of traditional lipid ratios and apolipoprotein ratios to predict cardiovascular risk in people with type 2 diabetes, Diabetologia: clinical and experimental diabetes and metabolism, vol.53, 9,pp 1846-1855
2007Abstract 3691: Features Of Metabolic Syndrome Identify Individuals With Type 2 Diabetes Mellitus At High Risk For Cardiovascular Events And Greater Absolute Benefits Of FenofibrateBarter, Philip; Copt, Samuel; Keech, Anthony (Tony); Pardy, Christopher; Best, James; D'Emden, Michael C.; Drury, P; Ehnholm, Christian; FIELD study investigators, Fenofibrate Intervention and Event Lowering in Diabetes; Kesaniemi, Y. Antero; Scott, Russell; Taskinen, M.; Tse, Dana; Central Clinical School: Heart Research Institute; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials CentreAbstract 3691: Features Of Metabolic Syndrome Identify Individuals With Type 2 Diabetes Mellitus At High Risk For Cardiovascular Events And Greater Absolute Benefits Of Fenofibrate, Circulation (Baltimore), vol.116, N/A,pp II_838-N/A
2009The effects of fenofibrate treatment on cardiovascular disease risk in 9795 people with type 2 diabetes and various components of the metabolic syndrome: the FIELD study.Fulcher, Greg; Keech, Anthony (Tony); Pardy, Christopher; Tse, D; D'Emden, Michael C.; Ehnholm, Christian; FIELD study investigators, Fenofibrate Intervention and Event Lowering in Diabetes; O'Brien, Richard; Scott, Russell; Taskinen, M.; Northern Clinical School: Medicine; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials CentreThe effects of fenofibrate treatment on cardiovascular disease risk in 9795 people with type 2 diabetes and various components of the metabolic syndrome: the FIELD study., Diabetes Care, vol.32,(3),2009,pp 493-498
2014HDL-C and HDL-C/ApoA-I Predict Long-Term Progression of Glycemia in Established Type 2 DiabetesGebski, Val; Jenkins, Alicia; Keech, Anthony (Tony); O'Connell, Rachel; Waldman, Boris; Davis, Timothy M. E.; Ng, Martin K C; Scott, Russell; Taskinen, M.; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials CentreHDL-C and HDL-C/ApoA-I Predict Long-Term Progression of Glycemia in Established Type 2 Diabetes, Diabetes Care, vol.37, 8, 2014,pp 2351-2358
2011Impact of metabolic syndrome and its components on cardiovascular disease event rates in 4900 patients with type 2 diabetes assigned to placebo in the FIELD randomised trialDonoghoe, Mark; Fulcher, Greg; Keech, Anthony (Tony); Pardy, Christopher; Colman, P. G.; Davis, T. M. E.; Manning, Patrick; O'Brien, Richard; Scott, Russell; Taskinen, M.; Watts, Gerald F.; School of Public Health: NH&MRC Clinical Trials Centre; Northern Clinical School: Medicine; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials CentreImpact of metabolic syndrome and its components on cardiovascular disease event rates in 4900 patients with type 2 diabetes assigned to placebo in the FIELD randomised trial, Cardiovascular Diabetology, vol.10, 1, 2011,pp 102-1-102-8
2007Long-term effects of fenofibrate on VLDL and HDL subspecies in participants with type 2 diabetes mellitusKeech, Anthony (Tony); Ehnholm, Christian; Hiukka, A.; Jauhiainen, Matti; Leinonen, E.; Sundvall, J.; Taskinen, M.; School of Public Health: NH&MRC Clinical Trials CentreLong-term effects of fenofibrate on VLDL and HDL subspecies in participants with type 2 diabetes mellitus, Diabetologia: clinical and experimental diabetes and metabolism, vol.50,(10),2007,pp 2067-2075
2015The relationship of fibroblast growth factor 21 with cardiovascular outcome events in the Fenofibrate Intervention and Event Lowering in Diabetes studyBarter, Philip; Hung, Wei Ting; Januszewski, Andrzej Szczesny; Jenkins, Alicia; Keech, Anthony (Tony); O'Connell, Rachel; Ong, Kwok; Rye, Kerry-Anne; Sullivan, David; Scott, Russell; Taskinen, M.; Xu, Aimin; Central Clinical School: Heart Research Institute; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials Centre; Central Clinical School: Heart Research Institute; Other or Unknown; NH&MRC Clinical Trials CentreThe relationship of fibroblast growth factor 21 with cardiovascular outcome events in the Fenofibrate Intervention and Event Lowering in Diabetes study, Diabetologia, vol.58, 3, 2015,pp 464-473
2009Relationships of HDL cholesterol, ApoA-I, and ApoA-II with homocysteine and creatinine in patients with Type 2 diabetes treated with fenofibrateBarter, Philip; Keech, Anthony (Tony); Simes, Robert John; Sullivan, David; Zannino, Diana; Ehnholm, Christian; Taskinen, M.; Whiting, Malcolm; Central Clinical School: Heart Research Institute; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials CentreRelationships of HDL cholesterol, ApoA-I, and ApoA-II with homocysteine and creatinine in patients with Type 2 diabetes treated with fenofibrate, Arteriosclerosis, Thrombosis, and Vascular Biology, vol.29, 6, 2009,pp 950-955
2004Significant lipid changes in a large-scale trial of fenofibrate to prevent cardiovascular disease in type 2 diabetesBarter, Philip; Forder, Peta; Keech, Anthony (Tony); Simes, Robert John; Best, James; FIELD study investigators, Fenofibrate Intervention and Event Lowering in Diabetes; Scott, Russell; Taskinen, M.; Central Clinical School: Heart Research Institute; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials CentreSignificant lipid changes in a large-scale trial of fenofibrate to prevent cardiovascular disease in type 2 diabetes, Journal of the American College of Cardiology, vol.43, 5,pp A462-A462